权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

CHARACTERIZATION OF HEMATIN DERIVED ANTICOAGULANT

血红素衍生抗凝剂的表征

基本信息

批准号：
3345351
负责人：
ROBERT L JONES
金额：
$ 11.17万
依托单位：
ROCKEFELLER UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
1985
资助国家：
美国
起止时间：
1985-09-30 至 1988-09-29
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/3345351
关键词：
affinity chromatography anticoagulants blood /lymphatic pharmacology blood coagulation tests chemical structure drug administration routes drug design /synthesis /production drug metabolism ferriheme gastrointestinal drug absorption heme high performance liquid chromatography nuclear magnetic resonance spectroscopy oxidation pharmacokinetics porphyrin metabolism thrombosis ultraviolet spectrometry

项目摘要

The project described in this proposal is designed to define the biochemical, biologic and pharmacologic significance of hematin-derived anticoagulant (HDA). HDA produces prolongation of clotting times in vitro and in vivo. HDA is a derivative or degradation product which is produced when hematin is allowed to stand in solution or when it is infused into rats. HDA will be purified and identified from in vitro and in vivo sources by chromatographic and spectroscopic techniques. This will test the hypothesis that HDA is a single derivative of hematin (heme) which is capable of interacting with coagulation proteins to produce profound functional effects. The mechanism of interaction of HDA with the specific proteins fibrinogen, thrombin and factor VIII:C will be defined by determining binding affinities and effects on enzymatic function with natural and synthetic substrates. The specific techniques of UV-Vis spectroscopy, equilibrium dialysis and antagonism with iron binding compounds will test the hypothesis that iron or a trace metal is involved in the interaction of HDA with clotting proteins. The production and mechanism of HDA in vivo will be defined with isolated hepatic heme metabolic systems and whole animals. This will test the hypothesis that HDA is a metabolic product of heme and that the mechanism is identical to that seen in vitro. Specific techniques involve radioisotope and pharmacologic probes. Finally, the pharmacologic potential of HDA will be determined by pharmacokinetic and efficacy studies utilizing radiolabelled HDA and various routes of administration. Completion of these studies will define the biochemical, physiologic and pharmacologic significance of HDA.

本建议书所述的项目旨在确定血红素衍生物的生物化学、生物学和药理学意义抗凝剂（HDA）。 HDA延长体外凝血时间和体内。 HDA是一种衍生物或降解产物，当血红素被允许在溶液中静置时，或者当它被注入大鼠 HDA将在体外和体内进行纯化和鉴定来源色谱和光谱技术。这将考验假设HDA是血红素（血红素）的单一衍生物，能够与凝血蛋白相互作用，功能效应。 HDA与特异性的蛋白质纤维蛋白原、凝血酶和因子VIII：C将被定义为测定结合亲和力和对酶功能的影响，天然和合成底物。紫外-可见分光光度计的具体技术光谱学、平衡透析和铁结合拮抗化合物将检验铁或微量金属参与的假设 HDA与凝血蛋白的相互作用。生产和 HDA在体内的机制将通过分离的肝血红素来定义代谢系统和整个动物。这将检验假设， HDA是血红素的代谢产物，其机制与在试管中看到的。具体技术涉及放射性同位素和药理学探针最后，HDA的药理学潜力将是通过使用放射性标记的药物代谢动力学和有效性研究确定 HDA和各种给药途径。完成这些研究将定义HDA的生物化学、生理学和药理学意义。